Can EDTA Change MRSA into MSSA? A Future Prospective!

Area of Science:

• Microbiology
• Infectious Diseases
• Drug Discovery

Background:

• Multidrug-resistant Staphylococcus aureus (MRSA), particularly hospital-acquired strains, poses a significant treatment challenge.
• Biofilm formation exacerbates multidrug resistance (MDR) in S. aureus, complicating infections.
• Vancomycin and linezolid resistance in staphylococci necessitates novel antimicrobial strategies.

Purpose of the Study:

• To evaluate the antibiofilm efficacy of ethylenediaminetetraacetic acid (EDTA) against clinical isolates of biofilm-forming MRSA.
• To investigate EDTA's potential to restore antibiotic susceptibility in MRSA.

Main Methods:

• MRSA strains were cultured to form biofilms on polystyrene microtitre plates.
• Biofilms were treated with varying concentrations of EDTA to assess antibiofilm activity.
• Antibiotic susceptibility testing was performed to determine changes in MRSA phenotype.

Main Results:

• EDTA demonstrated significant antibiofilm activity, inhibiting MRSA biofilm formation at 4mM.
• At 20mM, EDTA reduced and dissociated existing MRSA biofilms.
• This disruption facilitated antibiotic entry, converting MRSA strains to a Methicillin-sensitive S. aureus (MSSA) phenotype.

Conclusions:

• EDTA exhibits promising antibiofilm properties against MRSA.
• EDTA may serve as a valuable adjunct therapy for controlling MRSA and biofilm-related infections.
• Commercially available EDTA presents a potential future therapeutic option for challenging staphylococcal infections.